RankingsPricing
  1. US-listed companies
  2. Salarius Pharmaceuticals, Inc.
  3. Raw

Salarius Pharmaceuticals, Inc.SLRX

Market cap
$1.39M
P/E ratio
SummaryFinancials
Back to summarized table
Dec 31,
2014		Dec 31,
2015		Dec 31,
2016		Dec 31,
2017		Dec 31,
2018		Dec 31,
2019		Dec 31,
2020		Dec 31,
2021		Dec 31,
2022		Dec 31,
2023		Dec 31,
2024
Net loss-8,010,860-29,141,630-39,493,123-34,433,662-21,922,217-6,936,263-7,352,254-12,768,238-31,607,956-12,542,693-5,575,777
Depreciation, Depletion and Amortization-----127,40818,05819,1836,67710,0514,424
Equity-based compensation expense17742751,618319,391559,044796,803524,838273,730
Grant receivable writeoff---------130,000-
Grants receivable------4-2,245,506--1,480,490-
Prepaid expenses and other current assets370,396538,17817,409-148,881-600,121-91,582-1,140,11770,470-202,538-807,770-492,471
Accounts payable254,253621,393309,437819,357-1,661,910-519,276-2,782-310,6601-2,255,477334,141
Increase (Decrease) in Accrued Liabilities220,3752746,8791-2,951,420-320,637222,355170,131854,527-1,001,116-54,326
Net cash (used in) operating activities-6,480,866-20,746,118-32,051,873-27,722,198-23,598,660-11,580,096-10,311,363-10,200,197-17,595,321-12,846,137-4,525,337
Proceeds from Other Equity------1527272
Payments on note payable-----417,885974,435477,028-280,917466,505
Net cash provided by financing activities408122,0982,632118,01041828271
Net decrease in cash, cash equivalents and restricted cash-----9,356,412-2,392,881718-17,107,945-6,206,525-3,465,382
Cash paid for interest------8,6631,468-14,75410,643
Insurance premium financed by note payable---------570,560398,728